No Data
Hold Rating on Bristol-Myers Squibb Amid Patent Expirations and Speculative Prospects of Milvexian
Express News | Bristol-Myers Squibb Co : Jefferies Raises Target Price to $51 From $49
Regulators Expected To Approve Innovative Schizophrenia Treatment From Bristol Myers, Karuna
Market Whales and Their Recent Bets on BMY Options
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
Bristol Myers Squibb to Present Data Across Cardiovascular Portfolio at the European Society of Cardiology Congress 2024
RDK79 : Sorry, what’s a pdufa?